Matthew Squires
Novartis (United States)(US)Tris Pharma (United States)(US)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Cancer-related Molecular Pathways, Cancer Genomics and Diagnostics
Most-Cited Works
- → Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor(2017)336 cited
- → Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial(2014)263 cited
- → Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells(2003)192 cited
- → Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines(2009)171 cited
- → Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial(2020)152 cited
- → AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition